Corporate - Media & Press
ArrayIt® enhances SpotBot® 2 Personal Microarrayers with interstitial printing capabilities.
Sunnyvale, CA, January 8, 2008 – On January 8th, Arrayit announced the completion of software enhancements to its widely used ArrayIt® brand SpotBot® 2 Personal Microarrayers, the world’s only portable microarray robots. The SpotBot® 2 software enhancements allow all current SpotBot® 2 and and SpotBot® 2 Protein customers to print microarrays in an interstitial “orange packing” manner. Interstitial printing configures the printed spots in rows and columns, but consecutive rows are offset by one half spot distance such that the final printed microarray spots are more densely packed than traditional microarrays. The orange packing configuration allows a greater number of spots to be printed per unit area, thereby increasing the information provided by DNA and protein microarrays manufactured using the company’s SpotBot® 2 systems. Interstitial printing is currently available on ArrayIt® NanoPrint Enterprise Level Microarrayers, but the availability of this functionality on a personal microarrayer is a company and industry first.
TeleChem International is a privately owned high-tech company located in the heart of California’s Silicon Valley. Our products and services are provided by three corporate divisions: ArrayIt® Life Sciences Division, Chemicals Division, and a Diagnostics Division. The ArrayIt® Life Sciences Division offers a complete microarray technology platform that empowers >10,000 laboratories to use microarrays for human genome exploration, basic research, drug discovery, and myriad life sciences applications. Nearly every major research institution uses our patented microarray manufacturing technology (U.S. 6,101,946) and supporting products and services. The Chemicals Division provides import and export services and government contract manufacturing in the area of industrial chemicals for plastics, fire control, water treatment, agriculture, industrial and institutional compounding, and green energy. The Diagnostics Division holds key patents in the United States (6,913,879), Singapore (94899), New Zealand (523560), and other countries for its revolutionary “multi-patient” genotyping technology, which allows as many as 100,000 patients to be tested on a single microarray. Arrayit Diagnostics enables genotyping and disease diagnostics by providing testing kits, services, and technology transfer opportunities for disease screening and testing organizations.
Copyright 1993-2018 Arrayit Corporation. All rights reserved.